MedTrace Logo

AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Hepatobiliary Cancer Malignancies

NCT04835675 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 496

Last updated 2023-03-02

No results posted yet for this study

Summary

This study is a prospective, multicenter study aimed to develop and validate the performance of combined assays for cfDNA methylation markers and serum tumor markers in early hepatobiliary malignancies detection. Circulating tumor DNA (ctDNA) mutation, blood RNA markers and tissue will also be evaluated. The study will enroll approximately 496 participants, including participants with malignant or benign diseases of the hepatobiliary system.

Conditions

  • Hepatobiliary Malignancies

Interventions

DEVICE

Multi-cancer early detection test

Blood collection and multi-cancer early detection testing

Sponsors & Collaborators

  • Guangzhou BR

    collaborator UNKNOWN

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Mingxin Pan · Zhujiang Hospital

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-12
Primary Completion
2022-03-31
Completion
2022-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04835675 on ClinicalTrials.gov